How much cash does Gyre Therapeutics, Inc. generate?

Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.

What is Gyre Therapeutics, Inc.'s free cash flow?

After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.

Where does Gyre Therapeutics, Inc.'s cash flow data come from?

Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Gyre Therapeutics, Inc. GYRE Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Net income	——	——	$11.82M+35.3%	$8.74M-25.3%	$11.7M-34.6%
Depreciation and amortization	$2.62M+5.5%	$2.48M+8.5%	$2.29M+9.8%	$2.08M+24.7%	$1.67M+7.7%
Stock-based compensation	$9.23M+29.0%	$7.16M+129%	$3.13M+41.0%	$2.22M+67.1%	$1.33M+59.7%
Gain (loss) on sale of assets	——	——	——	——	——
Change in accounts receivable	——	——	——	——	——
Change in inventories	$3.18M-14.2%	$3.7M+41.7%	$2.61M-19.6%	$3.25M+7.8%	$3.01M+40.9%
Change in accounts payable	——	——	$256K—	——	——
Change in accrued liabilities	——	——	——	——	——
Change in other assets	——	——	——	——	$3.5M+773%
Change in other liabilities	——	-$47K-408%	-$9.25K+52.6%	-$19.5K-228%	$15.25K-33.7%
Change in income taxes payable/receivable	——	——	——	——	——
Change in operating lease liabilities	——	——	——	——	——
Net cash from operating activities	——	——	$3.88M—	——	——
Capital expenditures	$1.25M+4.7%	$1.19M+13.8%	$1.05M-2.3%	$1.07M-52.8%	$2.27M-4.6%
Proceeds from maturities/sales of investments	——	——	——	——	——
Proceeds from sale of businesses	$35K+16.7%	$30K-80.9%	$157K0.0%	$157K-56.0%	$357K-12.1%
Purchases of intangible assets	$43K-94.2%	$737K-52.4%	$1.55M—	——	——
Purchases of equity securities	——	——	——	——	——
Net cash from investing activities	——	——	-$4.33M+20.9%	-$5.47M+48.9%	-$10.7M+46.2%
Proceeds from issuance of common stock	$1.87M-20.7%	$2.36M—	——	——	——
Payment of debt issuance costs	——	——	——	$2.22M—	——
Net cash from financing activities	$23.06M-5.4%	$24.38M-2.6%	$25.02M+0.2%	$24.98M+796%	$2.79M+32.6%
Effect of exchange rate changes on cash	$578K+68.5%	$343K+979%	-$39K—	——	——
Net increase (decrease) in cash	——	——	$24.54M+20.3%	$20.39M+238%	-$14.74M+32.1%
Income taxes paid	$3.48M-38.2%	$5.62M+7.0%	$5.25M+2.9%	$5.1M-51.1%	$10.44M+22.6%
Accrued Interest On Bank Deposit	——	-$28K-112%	$240.5K-52.8%	$509K-34.5%	$777.5K-25.7%
Accrued Interest On Long Term Certificates Of Deposit	——	——	——	——	——
Bad Debt Expense And Other Non Cash Items	-$56K+11.1%	-$63K-250%	$42K-56.3%	$96K-73.7%	$365K+115%
Change In Fair Value Of Derivative Liabilities	——	——	——	——	$220K-7.9%
Change In Fair Value Of Long Term Receivables	——	——	——	——	$220K-7.9%
Deferred Income Tax Expense Benefit Net	-$1.66M-49.3%	-$1.11M+31.3%	-$1.61M-49.0%	-$1.08M-23.1%	-$880K+12.2%
Equity Gain Loss Of Unconsolidated Affiliates	-$79K-2.6%	-$77K-4.1%	-$74K—	——	——
Accrued expenses and other liabilities	——	——	——	——	——
Increase Decrease In Due To Related Parties	——	-$1K+42.9%	-$1.75K+99.1%	-$197.5K-156%	-$77.25K+6.9%
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable	——	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	——	$3.5M+773%
Net Proceeds From Cvr Liability Settlement	——	——	——	——	——
Noncash Lease Expense	$797K+2.6%	$777K-3.4%	$804K+6.9%	$752K+0.3%	$750K+11.6%
Payments to Acquire Equity Method Investments	——	——	——	——	——
Payments to Acquire Intangible Assets	$43K-94.2%	$737K-52.4%	$1.55M—	——	——
Payments to Acquire Restricted Certificates of Deposit	$18.56M+32.5%	$14.01M+11.4%	$12.58M0.0%	$12.58M-25.3%	$16.84M+8.8%
Proceeds from disposition of property, plant and equipment/other	$35K+16.7%	$30K-80.9%	$157K0.0%	$157K-56.0%	$357K-12.1%
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations	$578K+68.5%	$343K+979%	-$39K—	——	——
Fair Value Adjustment Of Warrants	-$541K+80.0%	-$2.71M-2.6%	-$2.64M-8.4%	-$2.43M+52.6%	-$5.13M+28.4%
Increase (Decrease) in Notes Receivables	$1.49M+29.7%	$1.15M+83.5%	$625K+168%	$233K-87.2%	$1.82M-54.9%
Income Taxes Paid, Net	$3.48M-38.2%	$5.62M+7.0%	$5.25M+2.9%	$5.1M-51.1%	$10.44M+22.6%
Free cash flow	$3.07M+1,807%	-$180K-106%	$2.9M—	——	——
Free cash flow	$3.07M+1,807%	-$180K-106%	$2.9M—	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Gyre Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

How much cash does Gyre Therapeutics, Inc. generate?: Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
What is Gyre Therapeutics, Inc.'s free cash flow?: After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
Where does Gyre Therapeutics, Inc.'s cash flow data come from?: Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.